Message Overview Research Laboratories Events / Publications Admission Access map
Home > Research Laboratories
Collaborative institutes Laboratoryof Immune Regulation Chugai Pharmaceutical CO.,LTD.
Nanobiology Laboratories Soft Biosystem Group Protonic NanoMachine Group Sensory Transduction Group Biomolecular Networks Laboratories Research Group of Lipid Biosignals Biomolecular Dynamics Group Developmental Biology Group Chromosome Replication Group Integrated Biology Laboratories Laboratory of Genetics Pathology Division KOKORO-Biology Group Cellular Biology Group Organismal Biosystems Laboratories Laboratory of Developmental Immunology Developmental Genetics Group Human Cell Biology Group Medicine and Pathophysiology Group Neuroscience Laboratories Visual Neuroscience Group Developmental and Functional Neuroscience Group Cognitive Neuroscience Group Cellular and Molecular Neurobiology Group Synaptic Plasticity Group Biophysical Dynamics Laboratories Physiological Laboratory Nonequilibrium Physics Group Functional Proteomics Group Nano-Biophotonics Group Biomedical Engineering Laboratories Systems Neuroscience Group Department of Molecular Genetics Laboratory of Intercellular Communications Laboratory of Stem Cell Research Laboratory of Protein Informatics Laboratory of Biocatalysis Science Collaborative institutes Collaborative institutes Laboratory of Immune Regulation Chugai Pharmaceutical CO., LTD. Optical Nano Device Group OMRON Corporation Professor KISHIMOTO Tadamitsu, MD, PhD. TEL +81-6-6879-4431 FAX +81-6-6879-4437 Associate Professor Shigemi Kinoshita, PhD. TEL   FAX   Assistant Professor Akihiro Kimura, PhD. TEL +81-6-6879-4432 FAX   Postal Mail Address Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University 1-3 Yamadaoka, Suita, Osaka 565-0871 Japan Lab Web site http://www.ifrec.osaka-u.ac.jp/jpn/laboratory/immuneregulation/index.php Collaborations Laboratory for Immune Signal, National Institute of Biomedical Innovation (http://www.nibio.go.jp/kisoteki/meneki_signal.html) 1   Interleukin-6 (IL-6)? IL-6 is a multifunctional cytokine produced by lymphoid and nonlymphoid cells; it regulates immune responses, acute-phase reactions, and inflammation. IL-6 signaling is mediated exclusively by the common signal-transducing component gp130, which is also essential for signal transduction of other cytokines of the leukemia inhibitory factor (LIF)/IL-6 family. Blocking IL-6 actions by use of a humanized antibody, tocilizumab, which targets the IL-6 receptor, has been proven to be therapeutically effective for rheumatoid arthritis, systemic juvenile idiopathic arthritis, Castleman disease and Crohn's disease. Regulatory system of IL-6 in Treg/Th17 development?Recently, a new subset of Th cells producing IL-17 (Th17) has been identified and shown to have a crucial role in the induction of autoimmune diseases such as rheumatoid arthritis and experimental autoimmune encephalomyelitis (EAE) as well as allergen-specific responses. Th17 cells differentiation is driven by the combination of IL-6 and TGF-?, whereas IL-6 inhibits the development of regulatory T (Treg) cells by TGF-?. Our current research is focused on demonstrating how IL-6 controls the generation of Treg/Th17 cells. We not only revealed the framework of cytokine signaling, including identification of the IL-6 receptor, gp130, NF-IL6, STAT3, and SOCS-1, but also led to the development of a new therapy for chronic inflammatory diseases. Recent studies demonstrated that Th17, distinct from Th1 and Th2, is the main pro-inflammatory CD4+ effector T cell involved in CIA and EAE. Understanding the precise mechanisms of Th17 differentiation by IL-6 will lead to resolve the immune disorder that causes immune-mediated inflammatory diseases. 　 figure 1 figure 2 figure 3 2

 

All rights reserved. Copyright © 2003 Graduate School of Frontier Biosciences, Osaka University